中国药业2023，Vol.32Issue(23)：37-42,6.DOI:10.3969/j.issn.1006-4931.2023.23.008
中美新型冠状病毒感染治疗指导性文件中药物治疗方案比较
Comparison of Drug Treatment Schemes in Coronavirus Disease 2019 Treatment Guidance Documents Between China and the United States
摘要
Abstract
Objective To provide a reference for the selection of treatment schemes for coronavirus disease 2019(COVID-19).Methods The COVID-19 Treatment Guidelines issued by the NIH[referred to as the National Institutes of Health(NIH)Guidelines]in March 2023 and the COVID-19 Diagnosis and Treatment Plans(Tenth Edition)issued by the National Health Commission of China(referred to as the Diagnosis and Treatment Plan)were analyzed to compare the similarities and differences between their treatment drugs and treatment plans for different populations.Results The treatment principles of the Diagnosis and Treatment Plan and the NIH Guidelines were giving antiviral treatment in the early stage,and giving immunotherapy and corresponding organ support treatment in the late stage.In terms of treatment drugs,the NIH Guidelines recommend three antiviral drugs[remdesivir,Nirmatrelvir Tablets/Ritonavir Tablets Co-Packaged(paxlovid)and monupiravir],and three types of immunotherapy drugs[corticosteroids,interleukin-6(IL-6)inhibitors,and Janus kinase(JAK)inhibitors].The Diagnosis and Treatment Plan recommended six antiviral regimens(azvudine,paxlovid,molnupiravir,monoclonal antibodies,Human COVID-19 Immunoglobulin for Intravenous Injection,and convalescent plasma),and two types of therapeutic drugs(corticosteroids and IL-6 inhibitor Tocilizumab),emphasizing traditional Chinese medicine treatment.The Diagnosis and Treatment Plan was too brief in describing the treatment plan,only providing alternative drugs based on the severity of the condition,while the NIH Guidelines provided specific preferred plans,alternative plans,and combined treatment plans.Conclusion The Diagnosis and Treatment Plan and NIH Guidelines have significant differences in treatment drugs and treatment plans for different populations.It is recommended to continue promoting clinical research on COVID-19 treatment drugs,refining clinical treatment plans,and paying attention to drug research for special populations such as children,pregnant women,and breastfeeding women.关键词
新型冠状病毒感染/美国国立卫生研究院指南/诊疗方案/抗病毒药物/免疫治疗药物Key words
COVID-19/COVID-19 Treatment Guidelines/Diagnosis and Treatment Plan/antiviral drugs/immunotherapy drugs分类
医药卫生引用本文复制引用
王丹丹,王陈萍,高霞,窦志华..中美新型冠状病毒感染治疗指导性文件中药物治疗方案比较[J].中国药业,2023,32(23):37-42,6.基金项目
江苏省药学会-正大天晴医院药学科研基金[Q202237]. （）
